


FUNDAMENTALS OF **DRUG DELIVERY**

EDITED BY

HEATHER A.E. BENSON | MICHAEL S. ROBERTS

ADRIAN C. WILLIAMS | XIAOWEN LIANG



WILEY

Fundamentals of Drug Delivery

Fundamentals of Drug Delivery

Edited by

Heather A. E. Benson

Curtin University of Technology, School of Pharmacy, Perth, Australia

Michael S. Roberts

University of Queensland, School of Medicine, Brisbane, Australia

Adrian C. Williams

University of Reading, School of Chemistry, Food and Pharmacy, Reading, UK

Xiaowen Liang

University of Queensland, Faculty of Medicine, Brisbane St Lucia, Australia

WILEY

This edition first published 2022
© 2022 by John Wiley & Sons, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Heather A. E. Benson, Michael S. Roberts, Adrian C. Williams, and Xiaowen Liang to be identified as the editors of this work has been asserted in accordance with law.

Registered Office

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

Editorial Office

111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data

Names: Benson, Heather A. E., editor. | Roberts, Michael S., 1949- editor.

| Williams, Adrian C., 1963- editor. | Liang, Xiaowen, editor.

Title: Fundamentals of drug delivery / edited by Heather A. E. Benson,

Michael S. Roberts, Adrian C. Williams, Xiaowen Liang.

Description: Hoboken, NJ : Wiley, 2022. | Includes bibliographical references and index.

Identifiers: LCCN 2021033395 (print) | LCCN 2021033396 (ebook) | ISBN

9781119769606 (cloth) | ISBN 9781119769651 (adobe pdf) | ISBN

9781119769675 (epub)

Subjects: MESH: Drug Delivery Systems | Drug Administration Routes

Classification: LCC RS199.5 (print) | LCC RS199.5 (ebook) | NLM QV 785 |

DDC 615/.6-dc23

LC record available at <https://lcn.loc.gov/2021033395>

LC ebook record available at <https://lcn.loc.gov/2021033396>

Cover Design: Wiley

Cover Image: © shutterstock\Yurchanka Siarhei

Set in 9.5/12.5pt STIXTwoText by Straive, Chennai, India

Contents

Preface *xvii*

List of Contributors *xix*

Part I Product Design, the Essence of Effective Therapeutics 1

1 Challenges and Innovations of Controlled Drug Delivery 3

Heather A.E. Benson and Michael S. Roberts

- 1.1 Background 3
- 1.2 Parenteral Dosage Forms 3
 - 1.2.1 Intravenous Route (IV) 4
 - 1.2.2 Intramuscular Route (IM) 5
 - 1.2.3 Subcutaneous Route (SC) 5
 - 1.2.4 Other Parenteral Routes 5
- 1.3 Oral Route and Delivery Systems 6
- 1.4 Nasal Drug Delivery 6
- 1.5 Pulmonary Drug Delivery 7
- 1.6 Transdermal Drug Delivery 7
- 1.7 Ocular Drug Delivery 9
- 1.8 Drug Delivery System Development Process 11
- 1.9 Conclusion 12
- References 12

2 Challenges in Design of Drug Delivery Systems 15

S. Narasimha Murthy, Shivakumar H.N, and Sarasija Suresh

- 2.1 Drug Properties to be Considered in Design of Controlled Release Products 19
- 2.2 Physicochemical Factors that Need to be Considered in Design of CRDDS 19
 - 2.2.1 Dose Size 19
 - 2.2.2 Molecular Weight/Size 19
 - 2.2.3 Aqueous Solubility 21
 - 2.2.4 Lipid Solubility and Partition Coefficient 25
 - 2.2.5 Physicochemical Stability 26
- 2.3 Biopharmaceutical Properties that Deserve Consideration in Design of Controlled Release Products 26
 - 2.3.1 Biological Half-life 26

- 2.3.2 Absorption 27
- 2.3.3 Metabolism 30
- 2.3.4 Presystemic Clearance 32
- 2.3.5 Margin of Safety 32
- 2.3.6 Adverse Effects 33
- 2.3.7 Therapeutic Need 33
- 2.3.8 Role of Circadian Rhythm 34
- 2.4 Conclusion 35
- References 35

3 Drug Delivery of the Future (?) 39

Adrian Williams

- 3.1 Introduction 39
- 3.2 Therapeutic Indicators 40
- 3.3 Drugs of the Future 43
- 3.4 Delivering the Drugs of the Future 45
- 3.5 A View to the Longer Term? 47
- 3.6 Conclusion 50
- References 50

4 The Pharmaceutical Drug Development Process: Selecting a Suitable Drug Candidate 53

Lionel Trottet

- 4.1 The Oral Drug Candidate: How to Get There and Questions to Answer 53
- 4.2 Challenges for Selecting a Topical Drug Candidate 55
- 4.3 Percutaneous Flux as a Surrogate Measurement of Skin Tissue Concentration 57
- 4.4 Learnings from Past Topical Drug Development of Factors Affecting Efficacy 58
- 4.5 Dermal Pharmacokinetics/Pharmacodynamics 62
- 4.6 Assessment of Systemic Exposure 63
- 4.7 Screening Cascade Approach to Select a Dermal Drug Candidate 64
 - 4.7.1 Efficacy (Lack of Target Engagement) 64
 - 4.7.2 Developability 65
 - 4.7.3 Local Safety 65
 - 4.7.4 Systemic Safety 65
- 4.8 Opportunities for Repurposing Molecules into Dermally Active Treatments for Cosmeceutical or Pharmaceutical Approaches 66
- 4.9 Conclusion 66
- References 67

5 Preformulation and Physicochemical Characterization Underpinning the Development of Controlled Drug Delivery Systems 73

Ronak Savla and Julien Meissonnier

- 5.1 When Is a Controlled Drug Delivery System Needed? 73
- 5.2 Optimizing Drug Characteristics 74
- 5.3 Defining the Product Profile 75
- 5.4 Preformulation and Physicochemical Characterization Underpinning Development of CDD 77

5.4.1	Feasibility and Risk Assessment	78
5.4.2	Solubility and Dissolution Rate	79
5.4.3	Permeability	82
5.4.4	Drug and Drug Product Particle Sizes	83
5.4.5	Solid-State Chemistry	84
5.4.5.1	Crystallinity and Polymorphism	85
5.4.5.2	Salts	85
5.4.6	Stability	85
5.4.7	Excipient Compatibility	86
5.4.8	Bulk Powder Properties	87
5.4.9	Drug Metabolism and Pharmacokinetic Modeling	88
5.4.9.1	Guiding the Design of CDD Dosage Forms	88
5.4.9.2	Establishing <i>In Vitro</i> – <i>In Vivo</i> Correlation (IVIVC)	89
5.4.9.3	Physiologically Based Pharmacokinetic (PBPK) Modeling Tools	89
5.5	Conclusion	89
	References	89

6 Mathematical Models Describing Kinetics Associated with Controlled Drug Delivery Across Membranes 95

Annette L. Bunge

6.1	Introduction	95
6.1.1	General Description	95
6.1.2	Governing Equations	98
6.1.2.1	Differential Equations	98
6.1.2.2	Dimensionless Differential Equations	98
6.1.2.3	Initial and Boundary Conditions	99
6.1.3	Other Derived Quantities	100
6.1.4	Dimensionless Variables and Groups	102
6.2	Model Solutions	104
6.2.1	Type A Models – Well-Stirred Vehicle on One Membrane	104
6.2.1.1	Model A1	104
6.2.1.2	Model A2	107
6.2.1.3	Model A3	112
6.2.1.4	Model A4	116
6.2.1.5	Model A5	120
6.2.1.6	Model A6	121
6.2.1.7	Model A7	123
6.2.1.8	Model A8	124
6.2.1.9	Model A9	125
6.2.1.10	Model A9a	128
6.2.1.11	Model A9b	130
6.2.1.12	Model A10	132
6.2.1.13	Model A11	136
6.2.1.14	Model A12	137
6.2.1.15	Model A13	138
6.2.2	Type B Models – Unstirred Semi-infinite Vehicle on One Membrane	140
6.2.2.1	Model B1	140

- 6.2.2.2 Model B2 143
- 6.2.3 Type C – Well Stirred Vehicle on Two Membranes in Series 145
- 6.2.3.1 Model C1 145
- 6.3 Solution Methods 149
- 6.3.1 Separation of Variables Solutions 150
- 6.3.1.1 Separating the Partial Differential Equation of N Independent Variables into N Ordinary Differential Equations 150
- 6.3.1.2 Choosing the Sign (Positive or Negative) on the Separation Constant 151
- 6.3.1.3 Finding the Constants of Integration and the Eigenvalues 152
- 6.3.1.4 Superposition 153
- 6.3.1.5 Finding the Remaining Constants of Integration 153
- 6.3.1.6 Guidelines for Using Separation of Variable Methods to Solve Partial Differential Equations 155
- 6.3.1.7 Methods for Making a Nonhomogeneous Partial Differential Equation or Nonhomogeneous Boundary Conditions Homogeneous 156
- 6.3.1.8 Choosing the Index Starting Value on the Sum of All Solutions (i.e. should $n = 1$ or 0 ?) 158
- 6.3.2 Laplace Transform Solutions 159
- 6.3.2.1 Using Laplace Transforms to Determine Lag Times, Steady-state Values and Other Derived Quantities 159
- 6.3.2.2 Inversion of Laplace Transformed Functions to Time Domain Functions by Method of Residues 161
- 6.3.2.3 Example A – Model A1 161
- 6.3.2.4 Example B – Model A10 165
- 6.3.3 Useful Identities 169
- References 169

7 Understanding Drug Delivery Outcomes: Progress in Microscopic Modeling of Skin Barrier Property, Permeation Pathway, Dermatopharmacokinetics, and Bioavailability 171

Guoping Lian, Tao Chen, Panayiotis Kattou, Senpei Yang, Lingyi Li, and Lujia Han

- 7.1 Introduction 171
- 7.2 Governing Equation 172
- 7.2.1 Homogenized Model 172
- 7.2.2 Microscopic Model 174
- 7.2.2.1 Solute Diffusion in SC Lipid 174
- 7.2.2.2 Solute Diffusion in SC Corneocytes 175
- 7.2.2.3 Solute Diffusion in Appendages 175
- 7.2.3 Numerical Methods 175
- 7.3 Input Parameters 176
- 7.3.1 SC Microstructure 176
- 7.3.2 SC Lipid–Water Partition 177
- 7.3.3 Diffusivity in SC Lipids 177
- 7.3.4 Binding to Keratin 179
- 7.3.5 Diffusivity in Corneocytes 181

7.3.6	Solute Diffusivity and Partition in Sebum	181
7.4	Application	183
7.4.1	Steady-State	183
7.4.2	Dermatopharmacokinetics	184
7.4.3	Systemic Pharmacokinetics	184
7.4.4	Shunt Pathway	185
7.5	Perspective	186
	References	188
8	Role of Membrane Transporters in Drug Disposition	193
	<i>Hong Yang and Yan Shu</i>	
8.1	Introduction	193
8.2	Distribution of Major Drug Transporters in Human Tissues	194
8.2.1	Major Drug Transporters in the Intestine	194
8.2.1.1	Drug Transporters Expressed in the Apical (Luminal) Membrane	194
8.2.1.2	Drug Transporters Expressed in the Basolateral Membrane	196
8.2.1.3	Expression of Drug Transporters in Different Intestinal Regions	197
8.2.2	Major Drug Transporters in the Liver	197
8.2.2.1	Drug Transporters Expressed in the Apical Membrane of Hepatocytes	197
8.2.2.2	Drug Transporters Expressed in the Basolateral (Sinusoidal) Membrane of Hepatocytes	199
8.2.2.3	Drug Transporters Expressed in the Bile Duct Epithelia (Cholangiocytes)	199
8.2.3	Major Drug Transporters in the Kidney	199
8.2.3.1	Drug Transporters Expressed in the Apical Membrane of Proximal Tubule Cells	200
8.2.3.2	Drug Transporters Expressed in the Basolateral Membrane of Proximal Tubule Cells	200
8.2.4	Major Drug Transporters in the Central Nervous System (CNS)	201
8.2.4.1	Drug Transporters Expressed in the Capillary Endothelial Cells of BBB	201
8.2.4.2	Drug Transporters Expressed in the Choroid Plexus Epithelial Cells of BCSFB	202
8.2.5	Major Drug Transporters in Other Tissues	202
8.2.5.1	Drug Transporters Expressed in Placenta Villi Epithelial Cells (Syncytiotrophoblasts)	203
8.2.5.2	Drug Transporters Expressed in Mammary Glands	203
8.2.5.3	Drug Transporters Expressed in the Blood–Testis-Barrier (BTB)	204
8.3	Role of Drug Transporters in Drug Disposition	205
8.3.1	Role of P-gp in Drug Disposition	206
8.3.2	Role of BCRP in Drug Disposition	207
8.3.3	Role of BSEP in Drug-Induced Cholestatic Liver Injury	214
8.3.4	Role of MRPs (MRP2, MRP3, and MRP4) in Drug Disposition	214
8.3.5	Role of OATPs (OATP1B1, OATP1B3, and OATP2B1) in Drug Disposition	215
8.3.6	Role of OATs (OAT1 and OAT3) in Drug Disposition	216
8.3.7	Role of OCTs (OCT1 and OCT2)/MATEs (MATE1 and MATE2-K) in Drug Disposition	217
8.4	Closing Remarks	218
	References	219

Part II Challenges in Controlled Drug Delivery and Advanced Delivery Technologies 231

9 Advanced Drug Delivery Systems for Biologics 233

May Wenche Jøraholmen, Selenia Ternullo, Ann Mari Holsæter, Gøril Eide Flaten, and Nataša Škalko-Basnet

- 9.1 Introduction 233
- 9.2 Considerations in Biologics Product Development 234
 - 9.2.1 Challenges Specific to the Route of Administration 234
 - 9.2.2 Challenges Related to Parenteral Administration 234
 - 9.2.3 Optimization of Dosage Regimens 234
- 9.3 Administration Routes for Biologics Delivery 235
 - 9.3.1 Parenteral Route 235
 - 9.3.2 Oral Route 236
 - 9.3.3 Buccal Route 237
 - 9.3.4 Sublingual Route 238
 - 9.3.5 Pulmonary Route 238
 - 9.3.5.1 Additional Concerns in Pulmonary Delivery 239
 - 9.3.6 Intranasal Route 239
 - 9.3.7 Trans(dermal) Delivery 240
 - 9.3.7.1 Gene Delivery 241
 - 9.3.7.2 Vaccine Delivery 242
 - 9.3.7.3 Protein Delivery 243
 - 9.3.8 Dermal Delivery of Growth Hormones 243
 - 9.3.9 Vaginal Route 247
- 9.4 Conclusion 251
- References 251

10 Recent Advances in Cell-Mediated Drug Delivery Systems for Nanomedicine and Imaging 263

Li Li and Zhi Qi

- 10.1 Introduction 263
- 10.2 Cell Types and Modification for Therapeutic Agent Delivery 264
 - 10.2.1 Cell Types 264
 - 10.2.1.1 Blood Cells 264
 - 10.2.1.2 Stem Cells 267
 - 10.2.1.3 Antigen Presenting Cells (APCs) 268
 - 10.2.1.4 Cell Membranes 268
 - 10.2.2 Cargo Loading Methods 269
- 10.3 Imaging and Tracking of Cell-Based Delivery Systems 270
 - 10.3.1 MRI 271
 - 10.3.2 PET 272
 - 10.3.3 X-Ray Imaging 272
 - 10.3.4 Multimodal Imaging Techniques 272
- 10.4 Cell-Mediated Drug Delivery Systems for Disease Treatment 272
 - 10.4.1 Cancer Therapy 272
 - 10.4.2 Immunotherapy 272

10.4.3	Brain-Related Diseases	274
10.4.4	Inflammatory Diseases	274
10.4.5	Theranostic Application	275
10.4.6	Others	275
10.5	The Mechanism of Cell-Mediated Delivery Systems for the Cell Therapies	275
10.5.1	Detoxification	276
10.5.2	Adhesive Mechanism	277
10.5.3	Homing Mechanism	278
10.6	The Administration Approach of Cell-Assist Drug Delivery System	278
10.7	Clinical Application of Cell-Based Delivery Systems	279
10.8	Conclusion and Outlook	279
	References	280

11 Overcoming the Translational Gap – Nanotechnology in Dermal Drug Delivery 285

Christian Zoschke and Monika Schäfer-Korting

11.1	Nanotechnology – Failure or Future in Drug Delivery?	285
11.2	Identification of the Clinical Need	286
11.3	Nanoparticle Design and Physicochemical Characterization	289
11.4	Biomedical Studies	294
11.4.1	Atopic Dermatitis	294
11.4.2	Psoriasis	295
11.4.3	Ichthyosis	296
11.4.4	Wound Healing	297
11.4.5	Infections	297
11.4.6	Skin Cancer	298
11.4.7	Alopecia Areata	299
11.5	Approaches to Fill the Translational Gaps in Nanotechnology	299
	References	303

12 Theranostic Nanoparticles for Imaging and Targeted Drug Delivery to the Liver 311

Haolu Wang, Haotian Yang, Qi Ruan, Michael S. Roberts, and Xiaowen Liang

12.1	Introduction	311
12.2	The Types of Theranostic NPs	312
12.2.1	Lipid- and Polymer-Based NPs	312
12.2.2	Mesoporous Silica NPs	312
12.2.3	Bio-nanocapsules	313
12.2.4	Iron Oxide NPs	313
12.3	Mechanisms of NPs Targeting the Liver	313
12.3.1	Passive Targeting to the Liver	313
12.3.2	Active Targeting to the Liver	314
12.3.3	Strategies for Combining Passive and Active Targeting	315
12.4	NPs in Liver Target Imaging	315
12.4.1	NP-Based Contrast Agents in Liver MRI	315
12.4.2	NP-Based Contrast Agents in Liver CT Imaging	316
12.4.3	NPs for Near-Infrared Fluorescence Imaging in Liver	316

12.5	NPs for Therapeutic and Drug Delivery in Liver Disease	316
12.5.1	NP Delivery System in HCC	316
12.5.2	NP Delivery System in Non-tumoral Liver Disease	318
12.6	Theranostic NPs in Liver Diseases	318
12.7	Conclusions	322
	References	323
13	Toxicology and Safety of Nanoparticles in Drug Delivery System	329
	<i>Klinton Wunnakup</i>	
13.1	Introduction	329
13.2	Lipid-Based Nanocarrier: Liposomes	329
13.3	Cellular Uptake Mechanism of Liposomes	330
13.4	Biodistribution, Clearance and Toxicity of Liposomes	331
13.4.1	Effect of Lipid Compositions on Liposome Distribution and Blood Circulation	331
13.4.2	Effect of Surface Charge on Liposome Distribution and Blood Circulation	333
13.4.3	Effect of Size on Liposome Distribution and Blood Circulation	333
13.5	Application of Liposomes in Drug Delivery	334
13.6	Inorganic Nanocarrier: Carbon Nanotubes	336
13.7	Cellular Uptake Mechanism of Carbon Nanotubes	337
13.8	Biodistribution, Clearance, and Toxicity of Carbon Nanotubes	337
13.9	Application of Carbon Nanotubes in Drug Delivery	342
13.10	Conclusion	342
	References	342
	Part III Administrative Routes for Controlled Drug Delivery	349
14	Controlled Drug Delivery via the Ocular Route	351
	<i>Peter WJ. Morrison and Vitaliy V. Khutoryanskiy</i>	
14.1	Introduction	351
14.2	Physiology of the Eye	352
14.2.1	Ocular Membranes; Conjunctiva, Cornea, and Sclera	353
14.2.2	Internal Ocular Structures	354
14.2.3	Anterior Chamber, Lens, and Vitreous Body	355
14.3	Ocular Disorders	355
14.3.1	Periocular Disorders	355
14.3.2	Intraocular Disorders	356
14.4	Controlled Drug Delivery Systems	357
14.4.1	Formulation Strategies	358
14.4.2	Mucoadhesive Systems	358
14.4.3	Solution to Gel <i>In Situ</i> Gelling Systems	359
14.4.4	Penetration Enhancers	361
14.4.5	Contact Lenses and Ocular Inserts	364
14.4.6	Intraocular Systems (Implants, Injectables, and Degradable Microparticles)	366
14.4.7	Phonophoresis and Ionophoresis	367
14.4.8	Topical Prodrugs	368
14.4.9	Microneedle Systems	368

14.5	Conclusions	369
	References	370
15	Controlled Drug Delivery via the Otic Route	377
	<i>Jinsong Hao and S. Kevin Li</i>	
15.1	Introduction	377
15.2	Anatomy and Physiology of the Otic Route	377
15.2.1	Anatomy of the Otic Route	377
15.2.2	Barriers Relevant to Inner Ear Drug Delivery	378
15.2.2.1	Blood Labyrinth Barrier	378
15.2.2.2	Round Window Membrane	380
15.2.2.3	Oval Window	380
15.2.2.4	Eustachian Tube	380
15.2.2.5	Tympanic Membrane	381
15.3	Controlled Drug Delivery Systems	381
15.3.1	Intratympanic Administration	381
15.3.1.1	Silverstein MicroWick	382
15.3.1.2	Round Window Microcatheter (μ Cath)	383
15.3.1.3	Gelfoam	383
15.3.1.4	Seprapak	383
15.3.1.5	Ozurdex as a RWM Implant	384
15.3.1.6	Propel Steroid-Eluting Stent	384
15.3.2	Trans-Oval Window Administration	384
15.3.3	Intracochlear Administration	385
15.3.3.1	Drug-Eluting Cochlear Implants	386
15.3.3.2	Microfluidic Reciprocating Reservoir	386
15.4	Conclusions	388
	References	388
16	Controlled Drug Delivery via the Nasal Route	393
	<i>Barbara R. Conway and Muhammad U. Ghori</i>	
16.1	Introduction	393
16.2	Anatomy and Physiology of the Nose	393
16.3	Absorption from the Nasal Cavity	395
16.3.1	The Epithelial Barrier	395
16.3.2	Absorption	395
16.4	Mucus and Mucociliary Clearance	398
16.5	Drug Delivery Systems	399
16.5.1	Solutions and Suspensions	400
16.5.2	Mucoadhesive Polymers	401
16.5.2.1	<i>In Situ</i> Forming Nasal Gels	401
16.5.2.2	Nasal Inserts	409
16.5.2.3	Microspheres and Nanospheres	410
16.5.2.4	Liposomes	411
16.5.2.5	Microemulsions and Nanoemulsions	413
16.5.2.6	Combination/Hybrid Products and Others	413
16.5.3	The Nasal Route and the Blood–Brain Barrier	415

- 16.5.4 The Nasal Route for Vaccinations 419
- 16.5.5 *In Vitro/in Vivo* Models for Nasal Absorption 421
- 16.6 Conclusion 423
- References 423

- 17 Controlled Drug Delivery via the Buccal and Sublingual Routes 433**
Javier O. Morales, Parameswara R. Vuddanda, and Sitaram Velaga
- 17.1 Introduction 433
- 17.2 Buccal and Sublingual Physiology and Barriers to Drug Delivery 434
 - 17.2.1 Saliva and Mucus 434
 - 17.2.2 Buccal and Sublingual Epithelium and Permeation Barrier 434
- 17.3 Controlled Drug Delivery Systems 436
 - 17.3.1 Tablets 436
 - 17.3.2 Films 437
 - 17.3.3 Gels, Ointments, and Liquid Formulations 438
 - 17.3.4 Spray 438
 - 17.3.5 Wafers 439
 - 17.3.6 Lozenges 439
 - 17.3.7 Advanced and Novel Drug Delivery Systems 439
- 17.4 Functional Excipients Used in Controlled Release Systems to Enhance Buccal and Sublingual Drug Bioavailability 440
 - 17.4.1 Permeation Enhancers 440
 - 17.4.2 Mucoadhesive Polymers 441
- 17.5 Conclusions 442
- Acknowledgments 443
- References 443

- 18 Controlled Drug Delivery via the Lung 449**
María V. Ramírez-Rigo, Nazareth E. Ceschan, and Hugh D. C. Smyth
- 18.1 Introduction 449
- 18.2 The Relevant Physiology of the Route Including the Barriers to Drug Delivery 449
- 18.3 Controlled Drug Delivery Systems 451
 - 18.3.1 Formulations 451
 - 18.3.1.1 Dissolution Rate Controlled 451
 - 18.3.1.2 Sustained Release Systems 451
 - 18.3.1.3 Drug Complexes 455
 - 18.3.1.4 Drug–Receptor Binding 456
 - 18.3.1.5 Drug Conjugates 457
 - 18.3.1.6 Drug–Polymer Matrix Particles 458
 - 18.3.1.7 Large Porous Particles 459
 - 18.3.1.8 Nanosystems 459
 - 18.3.2 Devices 459
 - 18.3.2.1 Controlling Lung Deposition Patterns 459
 - 18.3.2.2 Nebulizers 460
 - 18.3.2.3 Dry Powder Inhalers 461
 - 18.3.2.4 Pressurized Metered-Dose Inhalers 462
- 18.4 Conclusions 464
- Acknowledgments 464
- References 464

19 Controlled Drug Delivery via the Vaginal and Rectal Routes 471*José das Neves and Bruno Sarmento*

- 19.1 Introduction 471
- 19.2 Biological Features of the Vagina and Colorectum 472
 - 19.2.1 Vagina 472
 - 19.2.2 Colorectum 473
- 19.3 Controlled Drug Delivery Systems 474
 - 19.3.1 Vaginal Route 476
 - 19.3.1.1 Conventional Dosage Forms 476
 - 19.3.1.2 Removable Drug Delivery Systems 483
 - 19.3.1.3 Nanotechnology-based Drug Delivery Systems 486
 - 19.3.2 Rectal Route 489
 - 19.3.2.1 Dosage Forms 489
 - 19.3.2.2 Nanotechnology-based Drug Delivery Systems 493
- 19.4 Conclusions 494
 - Acknowledgments 494
 - References 494

20 Controlled Drug Delivery into and Through Skin 507*Adrian Williams*

- 20.1 Introduction 507
 - 20.1.1 Human Skin Structure and Function 507
 - 20.1.1.1 Biological Factors 507
 - 20.1.1.2 Skin as a Physical Barrier 508
 - 20.1.2 Drug Transport Through Skin 512
- 20.2 Controlled Drug Delivery into and Through Skin 513
 - 20.2.1 Skin Barrier Modulation 513
 - 20.2.1.1 Penetration Enhancers 514
 - 20.2.1.2 Ablation 515
 - 20.2.2 Controlled Release Transdermal and Topical Systems 515
 - 20.2.2.1 Supersaturation 516
 - 20.2.2.2 Reservoir Formation 518
 - 20.2.2.3 Film Forming Systems 518
 - 20.2.2.4 Vesicles 519
 - 20.2.2.5 Particles 520
 - 20.2.3 Device-Based Controlled Delivery 522
 - 20.2.3.1 Iontophoresis 523
 - 20.2.3.2 Sonophoresis 524
 - 20.2.3.3 Electroporation 525
 - 20.2.3.4 Microneedles 525
 - 20.2.3.5 Heat 526
 - 20.2.3.6 Other Devices 527
- 20.3 Combination Approaches 528
- 20.4 Conclusions 528
 - References 529

Index 535

Preface

Effective, controlled drug delivery has the potential to greatly impact the therapeutic outcome, clinical benefit, and safety of drugs in a wide range of diseases and health conditions. There are a large number of potentially useful drugs with limited effectiveness and/or safety concerns due to poor drug delivery. This may occur because a physiologically relevant concentration is not delivered to the target site, does not remain in contact for a sufficient period, or causes adverse effects because of the resulting high blood concentrations associated with indiscriminate release. Controlled drug delivery systems are designed to carry the drug and release it at the target site in a timely manner, facilitating its absorption and optimizing its physiological action. An effective controlled drug delivery system improves efficacy and safety by controlling the rate, time, and place of drug release within the body, thereby minimizing dose requirements and the potential to interact with non-target body sites that can contribute to undesirable side effects. Drug delivery has evolved from relatively simple systems to modern technologies designed to personalize medicines that have biologically precise drug release in response to real-time monitoring of body parameters.

Controlled drug delivery system development is rapidly evolving with an ever-increasing focus on advanced technologies that bring together a wide range of skilled professions including pharmaceutical scientists, chemical, mechanical, and electrical engineers, chemists, physicists, and clinicians. It is an exciting field that has helped to advance clinical outcomes in almost every health condition, ranging from negating the need for cold-chain storage thus allowing medicines to be transported to the most remote parts of the world, to precision targeting of drugs in cancer treatment. This book is designed to provide an insight into the fundamentals of drug delivery and the important processes in the development of controlled drug delivery systems.

The book is divided into three parts.

Part 1 (Chapters 1–8) introduces the concept of drug delivery and provides a perspective into the challenges, opportunities, and fundamental processes involved in the development of controlled drug delivery systems. It includes a historical perspective and a peek into the future of drug delivery. There is a focus on the drug development process, including the selection of pharmaceutical candidates and evaluation of their physicochemical characteristics with emphasis on the relevance to dosage form design. The role and application of mathematical modeling and the influence of drug transporters in pharmacokinetics and drug disposition complete this section.

Part 2 (Chapter 9–13) is focused on particular challenges in controlled drug delivery and advanced delivery technologies. This includes delivery systems for biologicals, an increasing drug category that presents enormous therapeutic opportunities and equally enormous delivery challenges. The application and recent advances in cell-mediated drug delivery are discussed, and there is a series of chapters on nanotechnology that include fundamentals, applications for targeted delivery, and discussion of the toxicological and safety issues.

Part 3 (Chapters 14–20) provides a “top to bottom” critique of the common administration routes for controlled drug delivery. Each chapter begins with a short introduction and then a more detailed discussion of the physiology pertinent to each administration route, focusing on the barriers to drug delivery. Controlled drug delivery systems that have been evaluated for each route are then discussed before some conclusions summarizing the state-of-the-art and potential future developments. Each chapter includes comprehensive references at the time of writing for those wishing to read the primary literature. *Controlled* drug delivery systems imply that control over dosing resides in the formulation with control over drug release and predictable drug delivery. However, it is apparent that, given the complexities of the biological barriers present for the administration routes, in several cases control over drug delivery arises predominantly from the biological barrier. Although strategies have been developed to reduce these barriers – for example the use of penetration enhancers – it is contentious whether these approaches truly allow *controlled* drug delivery. However, in seeking to provide a comprehensive critique of the current literature, such partially controlled systems have been considered.

We express our thanks to the authors who have contributed to this book. In each case, the chapters are authored by well-respected researchers in the field who have generously provided their knowledge and experience, and continue to contribute to advancing research in their fields. We are also grateful to Jonathan Rose and his team at Wiley who have brought the concepts and chapters to fruition, and shown remarkable patience in dealing with editors who agree with Albert Einstein that “time is an illusion”.

Australia
June 2021

Heather A. E. Benson
Michael S. Roberts
Adrian C. Williams
Xiaowen (Tina) Liang

List of Contributors

Heather A.E. Benson

Curtin Medical School
Curtin Health Innovation Research Institute
Curtin University
Perth, WA, Australia

Annette L. Bunge

Chemical and Biological Engineering
Department
Colorado School of Mines
Golden, CO, USA

Nazareth E. Ceschan

Departamento de Biología
Bioquímica y Farmacia, UNS
Bahía Blanca, Argentina

and

Planta Piloto de Ingeniería Química
(PLAPIQUI)
Consejo Nacional de Investigaciones
Científicas y Técnicas (CONICET) –
Universidad Nacional del Sur (UNS)
Bahía Blanca, Argentina

Tao Chen

Department of Chemical and Process
Engineering
University of Surrey
Guildford, UK

Barbara R. Conway

Department of Pharmacy
University of Huddersfield
Huddersfield, HD1 3DH, UK

Gøril Eide Flaten

Drug Transport and Delivery Research Group
Department of Pharmacy, Faculty of Health
Sciences
University of Tromsø The Arctic University of
Norway
Tromsø, Norway

Muhammad U. Ghori

Department of Pharmacy
University of Huddersfield
Huddersfield, HD1 3DH, UK

Shivakumar H.N

Department of Pharmaceutics
K.L.E College of Pharmacy
Bengaluru
India

Lujia Han

College of Engineering
China Agricultural University
Beijing, P.R. China

Jinsong Hao

Department of Pharmaceutical Sciences
College of Pharmacy & Health Sciences
Campbell University
Buies Creek, NC, USA

Ann Mari Holsæter

Drug Transport and Delivery Research Group
Department of Pharmacy, Faculty of Health
Sciences
University of Tromsø The Arctic University of
Norway
Tromsø, Norway

May Wenche Jøraholmen

Drug Transport and Delivery Research Group
Department of Pharmacy, Faculty of Health
Sciences
University of Tromsø The Arctic University of
Norway
Tromsø, Norway

Panayiotis Kattou

Department of Chemical and Process
Engineering
University of Surrey
Guildford, UK

Vitaliy V. Khutoryanskiy

Reading School of Pharmacy
University of Reading
Reading, UK

Li Li

Australian Institute for Bioengineering and
Nanotechnology (AIBN)
The University of Queensland
Brisbane, QLD, Australia

Lingyi Li

College of Engineering
China Agricultural University
Beijing, P.R. China

S. Kevin Li

Division of Pharmaceutical Sciences
James L Winkle College of Pharmacy
University of Cincinnati
Cincinnati, OH, USA

Guoping Lian

Unilever Research Colworth
Bedford, UK

and

Department of Chemical and Process
Engineering
University of Surrey
Guildford, UK

Xiaowen Liang

Therapeutics Research Group
The University of Queensland Diamantina
Institute
The University of Queensland
Translational Research Institute
Brisbane, QLD, Australia

Julien Meissonnier

Science and Technology
Catalent Pharma Solutions
Beinheim, France

Javier O. Morales

Center of New Drugs for Hypertension
(CENDHY)
Santiago, 8380494, Chile

and

Advanced Center for Chronic Diseases
(ACCDiS)
Santiago, 8380494, Chile

and

Department of Pharmaceutical Science and
Technology
School of Chemical and Pharmaceutical
Sciences
University of Chile
Santiago, 8380494, Chile

Peter W.J. Morrison

Reading School of Pharmacy
University of Reading
Reading, UK

S. Narasimha Murthy

Pharmaceutics and Drug Delivery
The University of Mississippi
113 Faser Hall, MS, USA

and

Institute for Drug Delivery and Biomedical
Research
Bengaluru, India

and

Department of Pharmaceutics
K.L.E College of Pharmacy
Bengaluru, India

and

Institute for Drug Delivery and Biomedical
Research
Bengaluru, India

José das Neves

i3S – Institute for Research and Innovation in
Health
University of Porto, Portugal

Zhi Qi

Australian Institute for Bioengineering and
Nanotechnology (AIBN)
The University of Queensland
Brisbane, QLD, Australia

María V. Ramírez-Rigo

Departamento de Biología
Bioquímica y Farmacia, UNS
San Juan 670, 8000 Bahía Blanca, Argentina

and

Planta Piloto de Ingeniería Química
(PLAPIQUI)
Consejo Nacional de Investigaciones
Científicas y Técnicas (CONICET) -
Universidad Nacional del Sur (UNS)
Bahía Blanca, Argentina

Michael S. Roberts

Therapeutics Research Centre
Basil Hetzel Institute for Translational Medical
Research

The Queen Elizabeth Hospital
Adelaide, SA, Australia

and

School of Pharmacy and Medical Sciences
University of South Australia
Adelaide, SA, Australia

and

Diamantina Institute
The University of Queensland, Translational
Research Institute
Brisbane, QLD, Australia

and

Therapeutics Research Group
The University of Queensland Diamantina
Institute
The University of Queensland, Translational
Research Institute
Brisbane, QLD, Australia

Qi Ruan

Therapeutics Research Group
The University of Queensland Diamantina
Institute, The University of Queensland
Translational Research Institute
Brisbane, QLD, Australia

Bruno Sarmento

INEB – Institute for Biomedical Engineering
University of Porto, Portugal

Ronak Savla

Science and Technology
Catalent Pharma Solutions
Somerset, NJ, USA

Monika Schäfer-Korting

Institute of Pharmacy (Pharmacology and Toxicology)
Freie Universität Berlin
Berlin, Germany

Yan Shu

Department of Pharmaceutical Sciences
School of Pharmacy, University of Maryland at Baltimore
Baltimore, MD, USA

Nataša Škalko-Basnet

Drug Transport and Delivery Research Group
Department of Pharmacy, Faculty of Health Sciences
University of Tromsø The Arctic University of Norway
Tromsø, Norway

Hugh D. C. Smyth

College of Pharmacy
The University of Texas at Austin
2409 West University Avenue
Austin, TX, United States

Sarasija Suresh

Institute for Drug Delivery and Biomedical Research
Bengaluru
India

Selenia Ternullo

Drug Transport and Delivery Research Group
Department of Pharmacy, Faculty of Health Sciences
University of Tromsø The Arctic University of Norway
Tromsø, Norway

Lionel Trottet

DMPK (Drug Metabolism and Pharmacokinetics)
Galapagos, Romainville, France

Sitaram Velaga

Kenox Pharmaceuticals Inc
Monmouth Junction
NJ, 08852, USA

Parameswara R. Vuddanda

Research Centre for Topical Drug Delivery and Toxicology
University of Hertfordshire
Hertfordshire, AL10 9AB, UK

Haolu Wang

Therapeutics Research Group
The University of Queensland Diamantina Institute, The University of Queensland Translational Research Institute
Brisbane, QLD, Australia

Adrian Williams

University of Reading
Reading, UK

Klintean Wunnapuk

Toxicology Division
Department of Forensic Medicine, Faculty of Medicine
Chiang Mai University
Chiang Mai, Thailand

Haotian Yang

Therapeutics Research Group
The University of Queensland Diamantina Institute, The University of Queensland Translational Research Institute
Brisbane, QLD, Australia

Hong Yang

Department of Pharmaceutical Sciences
School of Pharmacy
University of Maryland at Baltimore
Baltimore, MD, USA

Senpei Yang

College of Engineering
China Agricultural University
Beijing, P.R. China

Christian Zoschke

Institute of Pharmacy (Pharmacology and Toxicology)
Freie Universität Berlin
Berlin, Germany

Part I

Product Design, the Essence of Effective Therapeutics

1

Challenges and Innovations of Controlled Drug Delivery

Heather A.E. Benson¹ and Michael S. Roberts^{2,3,4}

¹Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, Australia

²Diamantina Institute, The University of Queensland, Translational Research Institute, Brisbane, QLD, Australia

³School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia

⁴Therapeutics Research Centre, Basil Hetzel Institute for Translational Medical Research, The Queen Elizabeth Hospital, Adelaide, SA, Australia

1.1 Background

A key health care advance over the last century has been the development of drug delivery systems that not only enable effective, safe, and reproducible delivery for optimal therapeutic benefit, but are also chemically and physically stable, aesthetically acceptable, convenient to use, cost-effective and optimized for the most appropriate mode of administration in their target population. There is a wide range of drug delivery systems available for a range of routes of administration, with the aim of achieving local or systemic effects, as shown in Figure 1.1. The most common route of administration is the oral route due to its convenience, cost, and patient acceptance. Injectables include the more common parenteral routes which are intradermal, subcutaneous (SC), intramuscular (IM), and intravenous delivery (Figure 1.1). In addition to the oral route, the most common nonparenteral routes of delivery are topical/transdermal, nasal, pulmonary, ocular, rectal, and vaginal (Figure 1.1). Drug absorption processes for nonparenteral administration generally involve passive and/or active transport across an epithelial barrier and carriage away into the systemic circulation by either local blood flow and/or via the lymphatic circulation. Topical delivery is used for a local effect, such as the treatment of pain, inflammation, or infection of the oropharynx (including nasal, buccal, and sublingual), eye, skin, lung, rectum, and vagina or for systemic delivery.

In this chapter, we introduce the routes of administration of therapeutic and diagnostic compounds to the body, the considerations in designing drug delivery systems, and some examples of the innovations that have contributed new controlled delivery products. The aim is to provide an overview of the topic, with considerable detail provided in the subsequent chapters in this and other volumes in this series.

1.2 Parenteral Dosage Forms

The parenteral route enables precise dosing for drugs that have a narrow therapeutic index, complete dosing for those with poor oral bioavailability to maintain optimal therapeutic concentrations, ready access in patients with swallowing difficulties, or an unconscious patient, and

Fundamentals of Drug Delivery, First Edition.

Edited by Heather A. E. Benson, Michael S. Roberts, Adrian C. Williams, and Xiaowen Liang.

© 2022 John Wiley & Sons, Inc. Published 2022 by John Wiley & Sons, Inc.




Figure 1.1 Routes of drug administration and associated dosage forms. Source: Khan and Roberts [1]. © 2018 Elsevier.

immediate blood levels of drugs in an emergency. It is used to deliver intravenous fluid replacement and parenteral nutrition fluids and is the preferred delivery route for emerging novel therapeutic molecules, such as proteins, peptides, and biologics. However, parenteral administration requires specialized personnel, and there is a risk of tissue damage, infection, and immune reactions. There is a requirement for sterility in processing, storage, and administration making it more expensive than other conventional drug products. The most common routes used for systemic delivery of a wide range of molecules including biopharmaceuticals, are SC, intravenous (IV), and IM [2] as shown in Figure 1.1. While many parenteral products are solutions, controlled release from formulations such as microparticles or implants composed of biodegradable polymers is also available.

1.2.1 Intravenous Route (IV)

The IV route is used to administer a drug directly into a vein, either as a bolus or by infusion, thus allowing administration of relatively large volumes of fluid. It avoids first pass metabolism and is the preferred choice for rapid pharmacological action, especially in emergencies and anesthesia. However, administration requires medical/nursing supervision, and there are associated risks of infection via the injection site, coagulation of infusion lines, and the possibility of red blood cell

hemolysis, pain, and phlebitis. Effective sterile manufacture and appropriate storage is required to prevent contamination with microbes, pyrogens, and inert particles.

1.2.2 Intramuscular Route (IM)

IM injection enables systemic dosing, high bioavailability, and a rapid onset of action of drugs such as antibiotics, steroids, and narcotic analgesics. It provides a low-cost alternative to IV dosing as demonstrated by Milkovich and Piazza, who reported 10 times lower cost associated with IM compared to IV antibiotics and the opportunity for self-administration and earlier hospital discharge [3]. The IM route avoids many of the administration-related risks of IV administration and can provide a safe, rapid drug administration option in the management of anaphylaxis, where IM dosing of epinephrine was associated with significantly less cardiovascular adverse events compared with IV bolus epinephrine (1.3% vs. 10%) [4] and can be administered rapidly by a teacher, relative, or member of the public. IM injection is associated with pain from needle insertion and care is required to avoid piercing arteries or causing nerve damage.

1.2.3 Subcutaneous Route (SC)

The SC route is cost-effective, amenable to self-injection, minimally invasive, and associated with fewer side effects than the IV route [5]. While adverse reactions to SC dosing are uncommon, edema, pain, inflammation, infection, abscesses, and injection-site reactions may be more common in the elderly [6]. The SC route offers the opportunity for placement of implants that can provide controlled drug release over prolonged periods. Portable devices for SC injection such as insulin pumps, auto injectors, and pen injectors allow optimal dose delivery and self-administration in the management of a range of conditions. Examples include insulin, epinephrine, interferon β -1a (multiple sclerosis), and Enbrel[®] (auto injectors containing the biologic etanercept for use in arthritis) (<https://www.enbrel.com/rheumatoid-arthritis/about-enbrel-for-ra, in>).

1.2.4 Other Parenteral Routes

Less common parenteral routes for drug delivery include epidural, intrathecal, intracerebroventricular (ICV), intra-arterial, intra-articular, intracavernous, intralesional, intraosseous, and intravesical injection and infusion. Epidural (outside the dura/spinal fluid sac) and intrathecal (inside sac) routes are used primarily for anesthesia/analgesia. ICV involves injection into the cerebrospinal fluid in cerebral ventricles to bypass the blood–brain barrier. It can be used for drug administration in neurodegenerative disorders such as spinal muscular atrophy or chemotherapeutic agents in gliomas. It is also used as a research tool. Intra-articular injections (into a joint) of anti-inflammatory drugs such as steroids are generally used for the treatment of inflammatory joint conditions such as arthritis, tendinitis, gout, and Carpal Tunnel Syndrome. Vasodilators and vasoconstrictors are administered by intracavernous injection (into the penis) to treat erectile dysfunction. Intralesional steroid therapy is most commonly used in the treatment of hypertrophic and keloid scars, acne cysts, and alopecia areata. Intraosseous infusion (IO) involves injecting directly into the marrow of a bone as an alternative to provide drugs or fluid when IV injection is not available, such as trauma patients with compromised IV access. A needle is inserted through the hard bone cortex into the soft bone marrow to provide immediate access to the vascular system [7]. Intravesicular injection involves administration into the bladder using a catheter, used primarily to instill immunotherapeutic and chemotherapeutic agents in the treatment of bladder cancer.

1.3 Oral Route and Delivery Systems

More than 75% of all doses are given as tablets and capsules due to their ease and low cost of manufacture, stability, convenience in carrying and storing, ease of use, effective taste-masking strategies, and less dosing errors [8]. However, frequent dosing of three to four times a day may be required for drugs with short or immediate elimination half-lives, potentially creating a high pill burden and adherence issues particularly in the older population who may be taking a number of medications to manage multiple conditions. There is clearly enormous potential for controlled drug delivery via the oral route, hence, we have devoted a volume in this series to this topic. Here we provide an overview of the formulation challenges and opportunities offered by the oral route.

While most oral formulations are swallowed intact, as shown in Figure 1.1, immediate release and soluble tablets offer quick therapeutic effect and are particularly suitable for people with swallowing problems such as children and the elderly. Formulation options include tablets that are allowed to effervesce in water, and oral disintegrating tablets, medicated gums, and oral films that can be sucked or chewed before swallowing. Sublingual (placed under the tongue) and buccal (placed between the gum and cheek) tablets, sprays, and patches deliver the drug through the mucosal surfaces of the mouth, providing the added advantage of avoiding first-pass metabolism.

Oral modified release dosage forms include delayed, extended, enteric coated, and other delivery systems that can improve the stability, efficacy, safety, and convenience for patients. They can offer reduced dosing frequency, with improved adherence, clinical outcomes, and a reduction in the need for further clinical intervention such as hospital readmissions [9]. Controlled release technologies include the use of biodegradable polymers, release rate-controlling membranes, microencapsulation, and bioadhesives to enhance drug contact time [10]. Multiparticulate controlled release formulations offer more flexibility for pediatric or elderly patients who have trouble swallowing as they can be filled into sachets or compressed into minitables [11].

1.4 Nasal Drug Delivery

Intranasal delivery systems are commonly used for treating local conditions (Figure 1.1) such as nasal allergy, congestion, and nasal infections, and are increasingly being used for delivery of opioids, respiratory medicines, vaccines, and other medicines for systemic effect. The thin and highly vascularized nasal mucosal layer enables a fast onset of drug action and avoidance of gastrointestinal tract and hepatic first-pass metabolism [12], and the nasal-associated lymphoid tissue (NALT) offers opportunities for vaccine delivery. The most common delivery systems are nasal sprays and drops administered to the anterior site of the nasal cavity, with the former showing twofold to threefold greater drug bioavailability [13]. The nasal cavity is designed to protect the lungs by filtering inhaled air via its hair follicles and mucous membrane, then transporting those particles down through the esophagus to the stomach by a mucociliary clearance process, thus exposing them to the degradative processes of the gastro-intestinal tract. This clearance process represents a challenge to nasal bioavailability as drug residence time in the nasooral cavity is decreased, resulting in reduced transport into the blood stream. Adhesive polymers, enzyme inhibitors, or the use of novel drug delivery formulations such as liposomes, nanoparticles, microspheres, microemulsions, and penetration enhancers can enhance drug retention and/or penetration across the nasal mucosa [14]. The most favorable candidates for nasal delivery, as shown in Table 1.1, are small lipophilic molecules such as propranolol ($M_W = 295.8$, $\log P_{o/w} = 2.7$), fentanyl ($M_W = 336.5$, $\log P_{o/w} = 4.1$), and estradiol ($M_W = 296.4$, $\log P_{o/w} = 4.3$) [15].